Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.01 EUR | +0.35% | +3.76% | +1.39% |
Jun. 06 | Ipsen Hires New Chief Corporate Affairs Officer | MT |
Jun. 05 | Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.39% | 123B | B+ | ||
+43.64% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.58% | 351B | C+ | ||
+19.72% | 328B | B- | ||
+8.78% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.03% | 167B | C+ | ||
+6.13% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi